Title:Phospho-eIF4E: A New Target for Acute Myeloid Leukemia
Volume: 22
Issue: 4
Author(s): Xiaofeng Jia and Hong Zhou*
Affiliation:
- Department of Hematology, Affiliated Hangzhou First peolpe’s Hospital, Zhejiang University School of Medicine, Hangzhou, 310006,China
Keywords:
Eukaryotic translation initiation factor 4E, p-eIF4E, increased p-eIF4E levels, therapeutic target, acute myeloid
leukemia, prognosis.
Abstract: The eukaryotic translation initiation factor 4E (eIF4E) is dysregulated in a wide variety
of cancers. Higher expression of eIF4E promotes tumorigenesis and has been implicated in cancer
development and progression. Regulation of eIF4E is particularly controlled through phosphorylation
yielding phospho-eIF4E (p-eIF4E). p-eIF4E is a signaling molecule that participates in several
pathways, including regulating various cancer-related processes. The role of phosphorylation of
eIF4E at Serine 209 on oncogenic transformation has been appreciated for the last 10 years and has
been under active investigation as a therapeutic target for cancers including acute myeloid
leukemia (AML), but the expression of p-eIF4E in the nucleus and the specific molecular mechanism
of action remain largely unresolved. It is selectively and highly expressed in AML where its
expression was associated with poor outcomes and prognosis. The purpose of this review is to describe
p-eIF4E as an indicator prognosis and a potential anticancer target for biological therapy of
AML.
